Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NU 206

Drug Profile

NU 206

Alternative Names: NU206; R-Spondin-1; RSpo-1

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin Pharma Company; Nuvelo
  • Developer ARCA biopharma Inc; Kyowa Hakko Kirin; Nuvelo
  • Class Growth factors; Proteins
  • Mechanism of Action Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone disorders; Inflammatory bowel diseases; Mucositis; Rheumatoid arthritis; Stomatitis; Wounds

Most Recent Events

  • 04 Oct 2012 Discontinued - Phase-I for Bone disorders in Australia (IV)
  • 04 Oct 2012 Discontinued - Phase-I for Mucositis in Australia (IV)
  • 04 Oct 2012 Discontinued - Phase-I for Wounds in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top